During my research on the pathogenesis of psoriasis and the therapeutic mechanisms of anti‐interleukin‐17A (anti‐IL‐17A) (Appendix) and anti‐interleukin‐23 (anti‐IL‐23) antibodies on psoriasis (Katayama, 2018), I considered whether these antibodies would also be effective against AD. Here, IL17A is linked to psoriasis.